ArticleMolecular psychiatry2024
N1-methylation of adenosine (m
Open access · hybridAbstract read
In one paragraph
Article in Molecular psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
9.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Mitochondrial enzyme dysfunction in Alzheimer's disease: a systematic review of human metabolic evidence.Metabolic brain disease · 2026Pooled it
- Review
- Edaravone provides neuroprotection against chronic heat stress-induced behavioral dysfunction through adaptive proteomic remodeling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Targeting NSignal transduction and targeted therapy · 2026Article
- TRMT10C promotes mitochondrial fission through transferrin receptor m1A methylation modification and aggravates the progression of atrial fibrillation.Journal of cell communication and signaling · 2026Article
- Neuromodulatory role and therapeutic potential of N 6 -methyladenosine RNA methylation in neurodegenerative diseases.Neural regeneration research · 2026Article
- ALKBH3 m1A Demethylase Deficiency Reduces Alzheimer's Amyloid-β Pathology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- NSUN6-Mediated m5C Modification of OAS2 Is Implicated in Neuronal PANoptosis during Perioperative Neurocognitive Disorders.Molecular neurobiology · 2026Article
- Integrated epigenetic networks in aging: from histone to RNA modifications.Journal of translational medicine · 2026Review
- Blood N1-methyladenosine (mCritical care (London, England) · 2026Article
- Discovering, Integrating, and Reinterpreting the Molecular Logic of Life: From Classical Theories of Heredity to an Extended Functional Perspective on the Central Dogma.Life (Basel, Switzerland) · 2026Review
- Site-Specific Mitochondrial RNA N1-Methyladenosine Demethylation via an Engineered MTS-PUF-ALKBH3 Fusion Protein.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Direct RNA sequencing enables improved transcriptome assessment and tracking of RNA modifications for medical applications.Nucleic acids research · 2025Article
- RNA methylation modifications in neurodegenerative diseases: Focus on their enzyme system.Journal of advanced research · 2025Review
- Roles of RNA modifications in aging and age-related diseases.BMB reports · 2025Review
- The Secret Life of NJournal of molecular biology · 2025Review
- ModiDeC: a multi-RNA modification classifier for direct nanopore sequencing.Nucleic acids research · 2025Article
- Feedback regulation between histone lactylation and ALKBH3-mediated glycolysis regulates age-related macular degeneration pathology.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Metabolic Markers Demonstrate the Heterogeneity of Walking Ability in Non-Disabled Community-Dwelling Older Adults.Metabolites · 2025Article
- The RMaP challenge of predicting RNA modifications by nanopore sequencing.Communications chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 3 countries.
Marko Jörg *Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Staudingerweg 5, 55128, Mainz, Germany.
Johanna E Plehn *Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Staudingerweg 5, 55128, Mainz, Germany.
Marco KristenInstitute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Staudingerweg 5, 55128, Mainz, Germany.
Marc LanderInstitute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Staudingerweg 5, 55128, Mainz, Germany.ORCID 0000-0002-2653-6132
Lukas WalzInstitute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Staudingerweg 5, 55128, Mainz, Germany.
Christine LietzInstitute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Staudingerweg 5, 55128, Mainz, Germany.
Julie WijnsInstitute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Staudingerweg 5, 55128, Mainz, Germany.
Florian PichotInstitute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Staudingerweg 5, 55128, Mainz, Germany.
Liliana Rojas-CharryInstitute of Molecular Medicine, University Medical Center Mainz, Langenbeckstr. 1, 55131, Mainz, Germany.
Katja M Wirtz MartinInstitute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Staudingerweg 5, 55128, Mainz, Germany.
Nicolas RuffiniInstitute for Human Genetics, University Medical Center Johannes Gutenberg University, 55131, Mainz, Germany.
Nastasja KreimInstitute of Molecular Biology (IMB), 55128, Mainz, Germany.
Susanne GerberInstitute for Human Genetics, University Medical Center Johannes Gutenberg University, 55131, Mainz, Germany.ORCID 0000-0001-9513-0729
Yuri MotorinEpitranscriptomics and RNA Sequencing (EpiRNA-Seq) Core Facility, UMS2008 IBSLor CNRS, Université de Lorraine-INSERM, Biopôle, 9 Avenue de la Forêt de Haye, 54505, Vandœuvre-lès-Nancy, France.
Kristina EndresDepartment of Psychiatry and Psychotherapy, University Medical Center of the Johannes Gutenberg University Mainz, Untere Zahlbacher Str. 8, 55131, Mainz, Germany.ORCID 0000-0002-1099-8287
Walter RossmanithCenter for Anatomy & Cell Biology, Medical University of Vienna, Währinger Straβe 13, 1090, Vienna, Austria.
Axel MethnerInstitute of Molecular Medicine, University Medical Center Mainz, Langenbeckstr. 1, 55131, Mainz, Germany.
Mark HelmInstitute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Staudingerweg 5, 55128, Mainz, Germany. mhelm@uni-mainz.de.
Kristina FriedlandInstitute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Staudingerweg 5, 55128, Mainz, Germany. kfriedla@uni-mainz.de.ORCID 0000-0001-8603-5957
Johannes Gutenberg University Mainz · DECentre National de la Recherche Scientifique · FRInstitute of Molecular Biology · DEMedical University of Vienna · AT
Funding
Deutsche Forschungsgemeinschaft (German Research Foundation) RR319 RMaP, TP A05
Abstract
One mechanism of particular interest to regulate mRNA fate post-transcriptionally is mRNA modification. Especially the extent of m
Indexed as
AdenosineAlzheimer DiseaseAmyloid beta-PeptidesElectron Transport Complex IMitochondriaRNA, MessengerAgedAged, 80 and overFemaleHumansMaleMethylationMethyltransferasesMitochondrial ProteinsAdenosineAmyloid beta-PeptidesElectron Transport Complex IMethyltransferasesMitochondrial ProteinsMT-ND5 protein, humanRNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.